KB Siripurapu

First name:
KB
Last name:
Siripurapu
Wooters, T. E., Smith, A. M., Pivavarchyk, M., Siripurapu, K. B., McIntosh, J. M., Zhang, Z., et al. (2011). bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. British Journal Of Pharmacology, 163(2), 346-57. https://doi.org/10.1111/j.1476-5381.2011.01220.x
View
Horton, D. B., Siripurapu, K. B., Norrholm, S. D., Culver, J. P., Hojahmat, M., Beckmann, J. S., et al. (2011). meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal Of Pharmacology And Experimental Therapeutics, 336(3), 940-51. https://doi.org/10.1124/jpet.110.175117
View
Beckmann, J. S., Siripurapu, K. B., Horton, D. B., Denehy, E. D., Vartak, A., Crooks, P. A., et al. (2010). The novel pyrrolidine nor-lobelane analog UKCP-110 cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal Of Pharmacology And Experimental Therapeutics, 335(3), 841-51. https://doi.org/10.1124/jpet.110.172742
View
Dwoskin, L. P., Wooters, T. E., Sumithran, S. P., Siripurapu, K. B., Joyce, B. M., Lockman, P. R., et al. (2008). N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. The Journal Of Pharmacology And Experimental Therapeutics, 326(2), 563-76. https://doi.org/10.1124/jpet.108.136630
View